A股異動 | 天華超淨(300390.SZ)漲超5% 疫苗注射器獲世衞組織認證
格隆匯1月4日丨天華超淨(300390.SZ)持續拉昇,現報25.95元,漲幅5.49%,最新總市值143.06億。公司公吿稱,近日,子公司宇壽醫療0.3ml自毀式固定劑量疫苗注射器產品通過世界衞生組織(WHO)的資格預審,取得了PQS證書。標誌着該產品符合世界衞生組織有關注射器的性能規範和測試程序,並被世界衞生組織列入產品信息數據庫。有助於上述產品被聯合國相關採購機構認可和使用,也有助於宇壽醫療推廣疫苗注射器產品。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.